Avalglucosidase alfa (GZ402666) ( DrugBank: Avalglucosidase alfa )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 256 | Muscle glycogenosis | 1 |
256. Muscle glycogenosis
Clinical trials : 180 / Drugs : 153 - (DrugBank : 30) / Drug target genes : 31 - Drug target pathways : 134
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05164055 (ClinicalTrials.gov) | February 15, 2022 | 16/11/2021 | A French Multicenter Phase 4 Open Label Extension Study of Long Term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Development Studies in France | A French Multicenter Phase 4 Open Label Extension Study of Long Term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Development Studies in France | Glycogen Storage Disease Type II | Drug: Avalglucosidase alfa (GZ402666) | Genzyme, a Sanofi Company | NULL | Not yet recruiting | 6 Months | N/A | All | 18 | Phase 4 | NULL |